News

ALX Oncology received FDA clearance for its Investigational New Drug (IND) application for ALX2004, an antibody-drug conjugate (ADC) designed...

Teva Pharmaceuticals has submitted a supplemental Biologics License Application to the FDA for AJOVY (fremanezumab-vfrm) to prevent episodic migraines...

Reunion Neuroscience presented the design of its REKINDLE Phase 2 clinical trial, which will evaluate RE104 for treating adjustment...

TG Therapeutics announced the publication of two articles, one examining the evolution of CD20 treatments for multiple sclerosis (MS)...

Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity. The...

iBio announced promising preclinical data for IBIO-600, a long-acting anti-myostatin antibody, and a first-in-class Activin E antibody, both targeting...

Tr1X, a clinical-stage biopharmaceutical company, received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to...

Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...

Arvinas presented positive Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, a protein implicated in...

Anavex Life Sciences announced positive data from its ATTENTION-AD trial, a long-term extension of a Phase 2b/3 study evaluating...